WEBULL
WebtradeDownload

HybridDIA Update Could Shape The Case For Immatics Stock

Simply Wall St · 1d ago
  • Immatics presented new data on its HybridDIA technology at the 25th Human Proteome Organization World Congress in Singapore, showcasing single-shot quantitative immunopeptidomics for low-input and spatially resolved applications. The presentations were delivered by Jonas D Förster, Parnian Kiani and Viktoria Kiani in late September 2026.
  • The HybridDIA focus underscores Immatics' effort to refine its antigen discovery toolkit, which sits at the core of its immunotherapy platform, R&D productivity and long-term development costs.
  • We will now explore how Immatics' HybridDIA immunopeptidomics work could reshape the investment narrative around its antigen discovery platform.

Scan other immunotherapy and healthcare names that could benefit from similar antigen discovery tailwinds through our curated 35 healthcare AI stocks, which are shaping the next wave of precision medicine.

What Is Immatics' Investment Narrative?

To own Immatics, you need to buy into a fairly pure R&D story. The business is still loss making, with a reported net loss of €206.549m on revenue of €41.704m, and the share price has fallen over the past year and longer. HybridDIA presentations at HUPO sharpen the pitch around antigen discovery, but they do not change the near term reality that execution depends on progressing Anzu cel and the broader TCR pipeline, managing trial complexity and keeping R&D spend under control.

In the short term, the bigger swing factors look like clinical readouts, any new partnering activity and access to funding, rather than conference data alone. Immatics trades on a P/S of 22.1x, above peer and industry averages, while analysts collectively see scope for upside but with limited agreement on outcomes. That premium, alongside ongoing losses and higher risk funding sources, makes the story very dependent on an investor’s confidence that this platform centered approach, including HybridDIA, eventually converts into commercially relevant products.

Even so, there is a less comfortable angle to the Immatics pitch once you factor in ...

There's only one way to know the right time to buy, sell or hold Immatics. Head to Simply Wall St's company report for the latest analysis of Immatics's Fair Value.

NasdaqCM:IMTX 1-Year Stock Price Chart
NasdaqCM:IMTX 1-Year Stock Price Chart

Exploring Other Perspectives

The Simply Wall St Community offers three fair value views on Immatics that range from 0.06x to 17.63x the current price, so you are looking at a massive gap in expectations. Those estimates all pre date the HUPO data. Use that spread as a prompt to test your own thesis and weigh alternative angles.

Explore 2 other Immatics fair value estimates, including one that suggests as much as 132% upside from the current price!

Form Your Own Verdict

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Immatics?

Once you have formed a view on Immatics, it can help to set that thesis against a wider watchlist of potential opportunities that fit different risk and return profiles.

  • If you want to focus on resilience first and potential upside second, start with our group of 31 resilient stocks with low risk scores and see which ones match your comfort level.
  • Income focused investors can scan for regular cash returns to shareholders by reviewing our selection of 7 dividend fortresses that clear a 5% yield hurdle.
  • For those who like to get in before the crowd, use our hand picked set of 19 high quality undiscovered gems with strong fundamentals as a source of fresh ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.